|
|
||||||||
EDITORIAL |
Ron Stall is with the Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pa. Thomas C. Mills is with the Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh.
Correspondence: Requests for reprints should be sent to Ron Stall, PhD, MPH, Graduate School of Public Health, University of Pittsburgh, 111 Parran Hall, 130 DeSoto Street, Pittsburgh, PA 15261 (e-mail: rstall{at}pitt.edu).
| INTRODUCTION |
|---|
|
|
|---|
| AIDS EMERGES FIRST WITHIN MARGINALIZED COMMUNITIES |
|---|
|
|
|---|
| AIDS IS A DISEASE OF DENIAL |
|---|
|
|
|---|
| AIDS PREVENTION WORKS, BUT MORE PROGRESS IS NEEDED |
|---|
|
|
|---|
| BIOMEDICAL RESPONSES MAY NOT BE ENOUGH TO END THE EPIDEMIC |
|---|
|
|
|---|
| CAREFUL ANALYSIS OF INITIAL SUCCESSES FOR FUTURE ACTION |
|---|
|
|
|---|
On the scientific front, the advances made since the advent of AIDS activism to support increases in funding for research in the fields of retrovirology, immunology, pharmacy, and the scientific study of sexual behaviors have been transformative. Structural interventions, which seek to change the contexts of risk through policy, legal, or environmental change, are also among the more successful responses to the epidemic. For example, testing the supply of transfused blood to eliminate HIV-infected plasma, a simple intervention, has reduced the scope of the epidemic and saved thousands of lives. Other structural interventions such as the use of antiretroviral medications to interrupt vertical HIV transmission from mother to child, needle exchange, and the 100% safe-sex program to prevent HIV transmission in brothels in Thailand have also had similarly powerful effects.
On the cultural front, there have been attempts at activism by groups such as ACT UP to confront the stigma associated with HIV, the goal of which is to change the cultural context in which stigmatized populations live. Although it is difficult to identify a thread common to these initial successes, it is notable that each of these initiatives has been characterized by the use of then-innovative scientific or theoretical advances that could be pragmatically fielded and maintained within specific community or institutional contexts.
| HOW WILL HISTORY JUDGE OUR ACTIONS? |
|---|
|
|
|---|
Certainly future historians will have ample evidence that we recognized that AIDS was one of the great public health catastrophes of our time and will show that, whatever else motivated our responses, we were not ignorant of the dangers of the disease, of the means by which it was transmitted, of the groups who were at gravest risk of transmission, or of effective strategies to prevent further HIV transmission. Future historians will conclude that we cannot escape responsibility for our failure to use effective, scientifically proven strategies to control the AIDS epidemic.
Future historians will be heartened that some of our leaders accurately perceived that AIDS was a global health problem that respected no borders. These historians will also be saddened to see that the resources to fight AIDS on an international basis were insufficiently marshaled in the crucial first decades of the fight against the calamity. They probably will be impressed with the rapid progress made in scientific understandings of the pathogenesis and treatment of AIDS, yet appalled by the instances when the ancient curses of racism and homophobia prevented us from fully responding to AIDS epidemics unfolding in our midst, as is the case now with African American MSM.22
Historians centuries hence will likely find our ongoing controversies over how best to fight the epidemic to be interesting windows on our evolving standards regarding sexual behavior and drug use, our views of social groups with whom we have limited contacts, and our ethical responsibilities to each other. They will also likely regard as tragic those instances when we allowed scarce resources to be used to support ideologically driven "prevention" that only served a particular political agenda. And from their distant vantage point, future historians would also tell us that, however difficult, controversial, and expensive we perceive the fight against AIDS to be, those costs are trivial compared with the price that we will all pay if we do not make every effort to bring AIDS to an end.
|
| Acknowledgments |
|---|
| Footnotes |
|---|
Accepted for publication February 25, 2006.
| References |
|---|
|
|
|---|
2. UNAIDS. AIDS Epidemic UpdateDecember, 2005. Geneva, Switzerland: UNAIDS; 2005.
3. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003, Abstract T1B1101. Presented at the National HIV Prevention Conference, June 1215, 2005, Atlanta, Ga.
4. Anderson J, Stall R. Increased reporting of male-to-male sexual activity in a national survey. Sex Transm Dis. 2002;29:643646.[Web of Science][Medline]
5. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2005, Vol. 16. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005:Table 17.
6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2005, Vol. 16. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005:Table 11.
7. Santelli J, Ott M, Lyon M, Rogers J, Summers D, Schleifer R. Abstinence and abstinence-only education: a review of US policies and programs. J Adolesc Health. 2006;38:7281.[CrossRef][Web of Science][Medline]
8. Semaan S, Des Jarlais D, Sogolow E, et al. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. J Acquir Immune Defic Syndr. 2002;30(Suppl 1):S73S93.
9. Mullen P, Ramirez G, Strouse D, Hedges L, Sogolow E. Meta-analysis of the effects of behavioral HIV prevention interventions on the sexual risk behavior of sexually experienced adolescents in controlled studies in the United States. J Acquir Immune Defic Syndr. 2002;30(Suppl 1):S94S015.
10. Neumann M, Johnson W, Semann S, et al. Review and meta-analysis of HIV prevention intervention research for heterosexual adult populations in the United States. J Acquir Immune Defic Syndr. 2002;30(Suppl 1):S106S117.
11. Herbst J, Sherba R, Crepaz N, et al., and the HIV/AIDS Prevention Research Synthesis Team. A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men. J Acquir Immune Defic Syndr. 2005;39(2): 228241.[Web of Science][Medline]
12. Cross J, Saunders C, Baretlli D. The effectiveness of educational and need exchange programs: A meta-analysis of HIV prevention strategies for infecting drug users. Qual Quant. 1998;32: 165180.[CrossRef]
13. Johnson B, Carey M, Chaudoir S, Reid A. Sexual risk reduction for persons living with HIV: Research synthesis of randomized controlled trials, 1993 to 2004. J Acquir Immune Defic Syndr. 2006;46:642650.
14. Crepaz N, Lyles C, Wolitski R, et al., for the HIV/AIDS Prevention Research Synthesis (PRS) Team. Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. Acquir Immunodefic Syndr. 2006;20:143157.
15. Kelly J, Somlai A, DiFranceisco W, et al. Bridging the gap between science and service of HIV prevention: transferring effective research-based HIV prevention interventions to community AIDS service providers. Am J Public Health. 2000;90:10821088.
16. Neumann M, Sogolow E, Kelly J. Turning HIV prevention research into practice: a special supplement to AIDS education and prevention. AIDS Educ Prev. 2000;12(Suppl):1145.[Web of Science][Medline]
17. Blum R. Uganda AIDS prevention: A, B, C and Politics. J Adolesc Health. 2004;34:428432.[Web of Science][Medline]
18. Haynes-Sanstad K, Stall R, Goldstein E, Everett R, Brousseau R. Collaborative Community Research ConsortiumA Model for HIV Research. Health Educ Behav. 1999;26:171184.
19. Ompad D, Galea S, Wu Y, et al. Acceptance and completion of hepatitis B vaccination among drug users in New York City. Commun Dis Public Health. 2004;7(4):294300.[Medline]
20. Wood E, Montaner J, Tyndall M, Schechter M, OShaughnessy M, Hogg R. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis. 2003;188(8): 11641170.[CrossRef][Web of Science][Medline]
21. Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. Int J Drug Policy. 2005;16S: S31S44.[CrossRef]
22. Millett G, Peterson J, Wolitski R, Stall R. Greater risk for HIV infection of Black men who have sex with men: a critical literature review. Am J Public Health. 2006;96:10071019.
This article has been cited by other articles:
![]() |
S. C. Quinn WE MUST FIGHT HIV/AIDS WITH SCIENCE, NOT POLITICS Am J Public Health, October 1, 2006; 96(10): 1723 - 1723. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |